Kornimate/medical-research-clean huggingface dataset:
fludarabine, rituximab, and alemtuzumab for b-chronic lymphocytic leukemia or small lymphocytic lymphoma

Conditions: Lymphoma, Small Lymphocytic; Lymphocytic Leukemia, Chronic

Summary: this purpose of this study is to assess the toxicity and the rate of complete and overall response using fludarabine, rituximab, and alemtuzumab to treat patients with b-chronic lymphocytic leukemia or small lymphocytic leukemia who have received previous treatment.

immunotherapy, or treatments that work by boosting immune function in the body, such as monoclonal antibodies have shown some efficacy against different types of leukemia. researchers have learned to manufacture antibodies outside of the human body that can bind to specific targets in cancer cells. monoclonal antibodies are designed to recognize different proteins on specific cancer cells. the current study combines two monoclonal antibodies, rituximab and fludarabine. rituximab attaches to a protein called the cd20 antigen that is found almost exclusively on the surface of b-cells with leukemia. once rituximab attaches to the protein, the immune system activates to kill the malignant b-cells. alemtuzumab works in a similar way by attaching with the cd25 antigen and also has activity in patients with p53 gene mutations. previous studies indicate that both rituximab and alemtuzumab separately have some efficacy against lymphocytic leukemia. research has also shown that fludarabine works against the disease. rituximab and fludarabine in combination appear to have a high response rate in patients. researchers are seeking to improve efficacy data by adding alemtuzumab to the combination of rituximab and fludarabine in this study. this study will evaluate the safety and efficacy of fludarabine, rituximab, and alemtuzumab in patients with previously treated b-cell lymphocytic leukemia and small lymphocytic leukemia. blood and bone marrow tests will assess genetic features associated with response to therapy, immune recovery, mechanisms of alemtuzumab's signaling, routes of drug resistance, and traces of residual disease following complete response in patients. patients in this study will receive fludarabine, rituximab, and alemtuzumab. these drugs will be administered through intravenous infusions. the treatment period will last 22 weeks. fludarabine will not be given during week one, 5 days during week 2, and 5 days during weeks 6, 10, 14, 18, and 22. rituximab will not be given during week one, 3 times the second week, and day one of weeks 6, 10, 14, 18, and 22. alemtuzumab will be given 3 times during week one, once during week 2, and day 2 of weeks 6, 10, 14, 18, and 22. the dosage amount of rituximab and alemtuzumab will be increased depending upon the degree of side effects. several tests and exams will be given throughout the study to closely monitor patients. treatments will be discontinued due to disease growth or unacceptable side effects.

Eligibility criteria:
inclusion criteria: * must have b-cll/sll * active disease * \>=1 prior systemic therapy * ecog ps 0-2. exclusion criteria: * pregnant or nursing women

Keywords: antigens, cd5 antigens, cd19 antigens, cd20
drug use investigation of jzoloft.

Conditions: Panic Disorder; Depression

Summary: the objective of this surveillance is to collect information about 1) adverse drug reactions not expected from the lpd (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first sertraline hydrochloride should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: patients need to be taking sertraline hydrochloride in order to be enrolled in the surveillance. exclusion criteria: patients not taking sertraline hydrochloride.
clinical trial to assess efficacy, safety, and tolerability of rasagiline mesylate 1 mg in patients with multiple system atrophy of the parkinsonian subtype (msa-p)

Conditions: Multiple System Atrophy

Summary: to test the clinical effect of rasagiline on subjects with msa of the parkinsonian subtype.


Eligibility criteria:
inclusion criteria: * subjects over 30 years old with a diagnosis of possible or probable msa of the parkinsonian subtype (msa-p) according to the gilman criteria (2008). * subjects who are less than 3 years from the time of documented msa diagnosis. * subjects with an anticipated survival of at least 3 years in the opinion of the investigator. * subjects who are willing and able to give informed consent. subjects who are not able to write may give verbal consent in the presence of at least one witness, and the witness should sign the informed consent form. exclusion criteria: * subjects receiving treatment with midodrine or other sympathomimetics within 4 weeks prior to baseline visit. * subjects with severe orthostatic symptoms as assessed by a score of ≥ 3 on unified multiple system atrophy rating scale (umsars) question 9. * subjects who meet any of the following criteria which tend to suggest advanced disease: 1. speech impairment as assessed by a score of ≥ 3 on umsars question 1 2. swallowing impairment as assessed by a score of ≥ 3 on umsars question 2 3. impairment in ambulation as assessed by a score of ≥ 3 on umsars question 7 4. falling more frequently than once per week as assessed by a score of ≥ 3 on umsars question 8 * subjects taking disallowed medications according to the locally approved azilect® label. * subjects taking monoamine oxidase (mao) inhibitors within 3 months prior to baseline visit. * subjects with hypertension whose blood pressure, in the investigator's opinion, is not well controlled. * subjects who, based on the investigator's judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. subjects with moderate or severe hepatic impairment. * subjects who have taken any investigational products within 60 days prior to baseline. * women of child-bearing potential who do not practice an acceptable method of birth control \[acceptable methods of birth control in this study are: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy, a double-protection method (condom or diaphragm with spermicide)\]. * pregnant or nursing women.
the anatomical reduction and functional recovery effects of two transvaginal apical slings on pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: the study is a prospective study at a single institution. investigators create strict inclusion and exclusion criteria, selecting 124 patients with pop(≥ii degree and have symptoms that need operation) . 62 patients in the intervention group accept extraperitoneal high uterosacral ligament suspension. the other 62 patients in the other group accept sacrospinous ligament suspension.

investigators evaluate all women's operation method, operation time, bleed volume, overactive bladder questionnaire, pfdi-20，iciq-sf, i-qol, pisq-12, pfiq-7, udi-6, pre- and post-operation (at 1 month, 3 months, 6months and 1 year).

Eligibility criteria:
inclusion criteria: age ≥30 years old; pelvic organ prolapse, with or without abnormal urination or defecation or sexual disturbance, which affects the quality of life pelvic organ prolapse quantitation (pop-q) is greater than or equal to those who are in stage ii and have symptoms and require surgery the patient agrees to conduct the study and can be followed up on time. exclusion criteria: those who cannot tolerate surgery and anesthesia those who need to remove the uterus those who have removed the uterus those who cannot be followed up on time.

Keywords: extraperitoneal high uterosacral ligament suspension
effects of everolimus in left ventricular hypertrophy after conversion from azathioprine: a pilot study

Conditions: Left Ventricular Hypertrophy

Summary: this is a prospective, open label, single-center study, in kidney transplant recipients with stable renal function for 12 and 120 months after transplantation, that are in use use of calcineurin inhibitors, azathioprine, and prednisone. the prevalence of left ventricular hypertrophy will be investigated before and after conversion of azathioprine to everolimus. this study will evaluate as primary objectives: the prevalence of left ventricular mass hypertrophy in renal transplant recipients with azathioprine therapy. and assess the ability of everolimus to reduce left ventricular mass after conversion from azathioprine, using sensitive methods such as mri. and as secondaries objectives: renal function (measured gfr) at 3 and 6 and 12 months after conversion, number and severity of episodes of acute rejection proven by biopsy, and the proteinuria at 3, 6 and 12 months after conversion.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years (black and white subjects); * kidney transplant recipients of living donor or deceased with creatinine clearance (measured / estimated) \> 50 ml /l for at least 12 months, receiving azathioprine with or without calcineurin inhibitor with or without prednisone. exclusion criteria: * the subject, in the opinion of the investigator, is not able to complete the study protocol; * multiple organ transplant recipient; * pregnant women * breastfeeding and childbearing age without contraceptive method * test for positive immunodeficiency virus (hiv) * treatment of acute rejection in the last 3 months * glomerulonephritis new relapse * new or polyomavirus nephropathy * protein / creatinine ≤ 150 mg / mmol or 24h proteinuria\> 500mg

Keywords: everolimus left ventricular hypertrophy
effect of water rinsing after topical fluoride application on dental plaque ph

Conditions: Dental Caries

Summary: the aim of this study was to determine whether rinsing with water or cleansing teeth after topical fluoride therapy affect the dental plaque ph.


Eligibility criteria:
inclusion criteria: * healthy people (without any systemic disease) * normal unstimulated salivary rate exclusion criteria: * active dental caries * taking any medication with any effect on saliva rate * taking antibiotic (or antibacterial mouth rinses) during last 4 weeks * usig fluoride mouth rinses during last 2 weeks.

Keywords: acidogenicity acidulated phosphate fluoride dental plaque water rinsing
role of preoperative d-dimer levels in the diagnosis of adnexal torsion

Conditions: Adnexal Torsion

Summary: adnexal torsion is the fifth most common gynecologic emergency. thirty percent of all cases of adnexal torsion occur in females younger than 20 years. approximately 5 of 100,000 females aged 1-20 years are affected, with girls older than 10 years at increased risk because of hormonal influences and gonadal growth that result in an increased frequency of physiologic and pathologic masses. the most common clinical symptom of torsion is sudden-onset abdominal pain that is intermittent, non-radiating, and associated with nausea and vomiting in 62% and 67% of cases respectively. moreover, abdominal tenderness is a clinical sign which is reported in up to 88% of patients with adnexal torsion. none of the following tests are useful in the diagnosis of adnexal torsion: leukocytosis, pyuria, c-reactive protein, and erythrocyte sedimentation rate. actually, transabdominal ultrasonography is the imaging modality of choice with a sensitivity of 92% and specificity of 96% in detecting adnexal torsion. a second-line imaging tool in the diagnosis of adnexal torsion is magnetic resonance, which may require a sedation in selected cases. consequently, there are no clinical or imaging criteria sufficient to confirm the preoperative diagnosis of adnexal torsion to date. therefore, patients with a clinical suspicion for adnexal torsion should undergo emergent diagnostic laparoscopy.


Eligibility criteria:
inclusion criteria: * female patients * age \< 18 years * presenting with lower quadrants abdominal pain * imaging suspicious for adnexal torsion exclusion criteria: * female patients aged \> 18 years * previous surgery for adnexal pathologies * clinical symptoms and imaging suggesting a different surgical pathology (i.e., appendicitis, gastroenteritis)

Keywords: d-dimer diagnosis adnexal torsion
regional anesthesia versus general anesthesia on circulating tumor cells (ctc)

Conditions: Breast Cancer

Summary: the purpose of the study is to determine whether the type of anesthesia during breast cancer surgery has any impact on the way a patient's immune system functions for a brief period after surgery. if the investigators find that one type of anesthesia versus the other is more beneficial to a patient's immune system, then the investigators may use this information to design a larger study to exam the effect of anesthesia better.

there are two different types of anesthesia that the investigators can use for subjects undergoing breast surgery. the first type is called "general anesthesia" (ga) which is when a person "goes to sleep" with a breathing tube and then receives intravenous (iv) pain medicine during and after surgery to minimize surgical pain. the other type of anesthesia is called "regional anesthesia" (ra), or "nerve blocks" which numb up the nerves that supply the breast area. by doing this type of anesthesia, subjects often don't go "to sleep" with a breathing tube, instead, they get heavy iv sedation and take a "deep nap" during the surgery.

Eligibility criteria:
inclusion criteria: * male and female subjects should be over 18 years of age and capable of providing informed consent indicating awareness of the investigational nature of this trial, in keeping with institutional policy * written informed consent must be obtained from each subject prior to entering the study * subjects with primary non-metastatic ajcc stages i, ii or iii, scheduled to undergo either unilateral mastectomy with or without sentinel lymph node biopsy or axillary dissection, or unilateral lumpectomy with sentinel lymph node biopsy or axillary lymph node dissection * able to stay overnight in the hospital post surgery exclusion criteria: * any subject younger than 18 years or older than 85 years of age * history of previous breast surgery (aside from biopsy), planned breast conserving operation (isolated lumpectomy) or reconstruction (rectus or latissimus flap) * american society of anesthesia (asa) classification of 4 or greater, or any contraindication to having regional anesthesia * any subjects who receives an intraoperative or postoperative blood transfusion during the period of venous blood sampling * subjects who are pregnant. exclusion of the possibility of pregnancy by testing (urine hcg) or by history (tubal ligation, hysterectomy, or menopause) is required prior to inclusion in the study * subjects with active infectious process at the site of proposed paravertebral injection * subjects with significant allergy to local anesthetics * subjects who convert from ra to ga during surgery

Keywords: anesthesia, circulating tumor cells
qt-prolongation in lung transplantation

Conditions: Disorder Related to Lung Transplantation

Summary: experimental intervention: electrocardiography. control intervention: none duration of intervention per patient/subject: 5 min, observation 6 months key inclusion criteria: * outpatients after lung transplantation (single, double or combined) * outpatients on the wait list for lung transplantation key exclusion criteria: • no informed consent

primary endpoint: • prevalence of significant qtc-interval prolongation (500 msec or above) after lung transplantation key secondary endpoint(s): * prevalence of any qtc-interval prolongation (\>440 msec ) after lung transplantation * prevalence of pq prolongation (200 msec sec or above) after lung transplantation * prevalence of qrs prolongation (120 msec or above) after lung transplantation * prevalence of qtc-prolonging drugs in drug regimen before and after lung transplantation * influence of long-term neo-macrolide (e.g. azithromycin) on qtc interval after lung transplantation * intra-individual difference of qtc interval before and after lung transplantation * incidence of any qtc-interval prolongation(\>440 msec ) after lung transplantation * incidence of any qtc-interval prolongation (\>440 msec or increase by 50msec or above) after initiation of new qtc prolonging drugs (especially neo-macrolides) * reversal of qtc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any qtc prolonging drug * assessment of safety: * incidence of new onset heart rhythm disorder during 6 months of follow-up

Eligibility criteria:
inclusion criteria: * outpatients after lung transplantation (single, double or combined) * outpatients on the wait list for lung transplantation exclusion criteria: * no informed consent

Keywords: lung transplantation electrocardiography macrolides qtc interval arrhythmia
the method of cotton padding promoting the rectovaginal fistula surgery

Conditions: Healing of the Wound After Rectovaginal Fistula Surgery

Summary: the method of cotton padding (mcp) was summarized by combining with many years clinical experience and the traditional ancient books.the mcp could be used in rectovaginal fistula (rvf) post operation effectively,in order to improve the wound.the research aim is to observe if the mcp could influence the time of staying in hospital, healing time after rvf surgery.

the method of cotton padding (mcp) originating from extensive and profound traditional chinese medicine (tcm) and being one of traditional surgical treatments of chronic wounds,could promote the wound healing after rvf surgery in previous clinical experience. the research aim is to observe if the mcp could influence the time of staying in hospital, healing time,quality of life,complications after rvf surgery. also,investigators will try to explain the mechanism about the mdm improving the wound healing by the chinese architectural theory and the nanomechanical properties.

Eligibility criteria:
inclusion criteria: * rectovaginal fistula because of parturition,stapler,traumatic injury. exclusion criteria: * rectovaginal fistula because of ibd,radiation,cancer.

Keywords: rectovaginal fistula healing cotton padding
comparison of functional outcome in patients after hip arthroplasty depending on surgical approach

Conditions: Hip; Osteoarthritis

Summary: the aim of the study will be to compare functional outcomes of the two surgical hip approaches in total hip arthroplasty: anterior, posterolateral and anterolateral. surgical approach may have influence on patients functional outcome.

patients with primary hip osteoarthritis will be included in a randomized controlled trial and assigned to total hip arthroplasty using one the of hip approaches: anterior or anterolateral. subjects will be assessed preoperative and 3 and 12 moths postoperative. biomechanical gait parameters will be collected using tree-dimensional motion analysis system "bts smart". evaluation of the function of the middle gluteal muscle with superficial emg (semg) percutaneous surface electromyography. fatigue assessment (mean frequency and amplitude) of the gluteus medius muscle during isometric muscle contraction. balance and coordination as well as fall risk will be assessed with use of dynamometric biodex balance platform. the study will determine the values of individual indicators: general stability index (ows), anterior-posterior stability index (apw), the median lateral stability index (mlw) and the fall risk index (ru). subjective assessment will be conducted with use of visual analogue scale, womac index, oxford hip score, the short form-36 (sf-36) and harris hip score

Eligibility criteria:
inclusion criteria: * patient's consent for anticipation in the study * bmi less than 35 * ability to walk the distance of 10m and stand up from the chair * arthroplasty in one hip exclusion criteria: * patient's lack of consent for anticipation in the study * neurological diseases * balance disorders * reoperations in the area of endoprosthesis * muscles diseases * rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis) * dizziness, vasovagal syncope

Keywords: total hip arthroplasty surgical approach
cross cultural adaptation of international physical activity questionaire short form in urdu version

Conditions: Heart Diseases

Summary: the ipaq-sf scale is widely used in our clinical settings. the translated version of ipaq-sf scale in urdu will help the clinician in collecting data thus, easy to understand for the patient and making it more desirable in our region.

the purpose of study is to translate ipaq-sf (international physical activity questionnaire- short form) scale in urdu and to determine the validity \& reliability of ipaq-sf in urdu version. patients who are at high risk of chronic diseases such as cardiovascular disease, diabetes, and hypertension age between 30 to 65 years and can understand urdu and english language are included in my study. 6mint walk test performed to assess aerobic capacity and endurance and physical activity over the last seven days is recorded on the translated version of ipaq-sf in urdu and then back of urdu into english.

Eligibility criteria:
inclusion criteria: * patients who have chronic diseases, such as cardiovascular, pulmonary and metabolic disease will consider as high risk, those who have more than two number of cad risk factor will categorize as mild and patients have less than two risk factor of cad will consider as low risk factor.(acsm risk stratification guide lines) those who can read and understand english and urdu as well. exclusion criteria: * those with known parkinson's disease, cerebrovascular disease or dementia. individuals have difficulty with reading because of low educational level

Keywords: ipaq-sf 6mwt rate pressure product
improving quality of icd-10 coding using ai: protocol for a crossover randomized controlled trial

Conditions: Gastrointestinal Diseases

Summary: the goal of this randomised trial is to learn about the role of ai in clinical coding practice. the main question it aims to answer is: can the ai-based cac system reduce the burden of clinical coding and also improve the quality of such coding? participants will be asked to code clinical texts both while they use our cac system and while they do not.

once participants are recruited, they are randomly allocated to 2 groups without allocation concealment. allocation concealment will not be relevant for clinical coders since it is known whether a participant is assisted or not, and we will not develop a placebo coding assistant. we will, however, conceal the allocation of subjects for the analyses. in total, participants will code 20 clinical notes, where each note belongs to a single patient. the participants are asked to complete the experiment in 1 sitting without interruptions, and they cannot revisit or go back to previous notes. in the event that participants are interrupted, they are asked to exit the experiment, and any incomplete records are discarded as invalid. the user study process can be summarized in the following steps: 1. study participants are randomly allocated to group 1 and group 2. 2. to prepare participants for the experiment, a short video tutorial is played after the consent form is signed and right before the clinical coding task commences. 3. in period 1 with 10 clinical notes, group 1 uses the control interface, while group 2 uses the intervention interface. 4. data are logged in the background using button presses (eg. time, assigned codes, and comments). 5. then, there is an immediate crossover to period 2 for the last 10 clinical notes. 6. data continue to be logged in the background using button presses. 7. at the end, participants in both groups will complete the system usability scale.

Eligibility criteria:
inclusion criteria: * participant has coded clinical texts before, preferably icd-10 coding * is a healthcare professional, eg. clinician, nurse, professional coders * can understand swedish exclusion criteria: * participants outside norway and sweden